Evidence map›Paper›PMID 33838999›Full record

ArticlePharmacological research2021

Corrigendum to "Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19" [Pharmacol. Res. 164 (2021) 105402].

Emilio Di Maria, Paolo Martini, Massimo Gennarelli

Open access · greenAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Emilio Di MariaDept. of Health Sciences, University of Genova, Italy; Unit of Medical Genetics, Galliera Hospital, Genova, Italy. Electronic address: emilio.dimaria@unige.it.
Paolo MartiniDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Massimo GennarelliDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
University of Brescia · ITUniversity of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33838999
PMCPMC8025071
OpenAlexW3148040148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.